EP0000150B1 - Dihydropyridine derivatives, process for their production and pharmaceutical compositions containing them. - Google Patents

Dihydropyridine derivatives, process for their production and pharmaceutical compositions containing them. Download PDF

Info

Publication number
EP0000150B1
EP0000150B1 EP78100165A EP78100165A EP0000150B1 EP 0000150 B1 EP0000150 B1 EP 0000150B1 EP 78100165 A EP78100165 A EP 78100165A EP 78100165 A EP78100165 A EP 78100165A EP 0000150 B1 EP0000150 B1 EP 0000150B1
Authority
EP
European Patent Office
Prior art keywords
carbon atoms
compound
formula
alkyl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
EP78100165A
Other languages
German (de)
French (fr)
Other versions
EP0000150A1 (en
Inventor
Peter Dr. Neumann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of EP0000150A1 publication Critical patent/EP0000150A1/en
Application granted granted Critical
Publication of EP0000150B1 publication Critical patent/EP0000150B1/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention relates to dihydropyridine derivatives.
  • the present invention provides compounds of formula I, wherein
  • alkyl of 1 to 6 carbon atoms is preferably of 1 to 4 carbon atoms, especially of 1 to 2 carbon atoms.
  • Any alkyl, alkoxy, alkylthio or or alkylsulfonyl radical of 1 to 4 carbon atoms is preferably of 1 or 2 carbon atoms.
  • the alkyl moiety of cycloalkylalkyl or cycloalkyalkoxy is conveniently methyl.
  • Halogen means fluorine, chlorine or bromine and is especially chlorine.
  • Cycloalkyl or the cycloalkyl moiety of cycloalkylalkyl or cycloalkylalkoxy is conveniently cyclopropyl or cyclopentyl or cyclohexyl.
  • alkenyl, alkynyl, alkenyloxy, alkynyloxy or phenylalkenyl is preferably not in the ⁇ , ⁇ position.
  • Alkenyl, alkenyloxy, alkynyl or alkynyloxy preferably has 3 to 5 carbon atoms.
  • Alkenyl or the alkenyl moiety of alkenyloxy is conveniently allyl or 2-methylallyl.
  • Alkynyl or the alkynyl moiety of alkynyloxy is conveniently propynyl.
  • Phenylalkenyl preferably has the trans-configuration and is for example cinnamyl.
  • R is optionally substituted phenylalkyl
  • the phenyl group is preferably unsubstituted.
  • the phenyl group is di- or tri-substituted, preferably the substituents are the same.
  • R 3 and/or R 4 is alkoxy, this is preferably ethoxy or methoxy.
  • R 3 and/or R 4 is alkoxyalkoxy or hydroxyalkoxyalkoxy, preferably the carbon chain between the two ether oxygen atoms is of 2 carbon atoms.
  • the hydroxy group of hydroxyalkoxy or of hydroxyalkoxyalkoxy is preferably not attached to the carbon atom attached to an ether oxygen atom.
  • R is preferably hydrogen.
  • R 2 is conveniently identical to R 5 .
  • R 2 and/or R 5 is preferably methyl.
  • R 3 and/or R 4 is preferably alkoxy or alkoxyalkoxy, especially n-butyloxyethoxy.
  • R . is conveniently halogen, alkyl or alkoxy, or especially hydrogen.
  • R 6 is conveniently adjacent to the dihydropyridine moiety which in turn is conveniently in the 4-position.
  • the process may be effected in conventional manner for analogous dihydropyridine syntheses, e.g. according to Hantzsch.
  • R 2 is identical to R 5 and R 3 is identical to R 4
  • At least 2 moles of a compound of formula IV per mole of a compound of formula II are present.
  • a compound of formula II may be reacted with a compound of formula VI, wherein R 1 , R 4 and R 5 are as defined above.
  • At least 2 moles of a compound of formula VI per mole of a compound of formula II are present.
  • R is hydrogen.
  • a compound of formula VI may be formed as an intermediate during the reaction of a compound of formula IV and a compound of formula V.
  • R 2 , R 3 , R 4 and R 5 are not identical that more than one isomer of formula I may be formed. If so these may be separated in conventional manner, e.g. by thin layer chromatography.
  • the reaction is a ring cyclisation.
  • Z and Z' are both oxygen, then an amine of formula V should be present.
  • reaction may be effected conveniently in solution.
  • a suitable solvent is water, ethanol, dioxane, dimethyl formamide, dimethyl sulphoxide, pyridine or glacial acetic acid.
  • Suitable reaction temperatures may be from 20 to 160°C, preferably from 60 to 120°C.
  • the compounds of formula I exhibit pharmacological activity. In particular, they lead to a dilation of the coronary vessels as demonstrated by the results of tests measuring the blood flow to the myocardium of an anaesthetised cat by means of the microsphere method upon the administration of the active substance i.v. or i.d.
  • the compounds of formula I also possess a favourable effect against angina pectoris, as shown by the increase of the coronary flow of an anaesthetised cat upon administration of the active substance.
  • the compounds of formula 1 are therefore indicated for use in the treatment of coronary insufficiency.
  • an indicated daily dose is from about 5 to 100 mg, conveniently administered in divided doses 2 to 4 times a day in unit dosage form containing from about 1.25 to about 50 mg, or in sustained release form.
  • the compounds of formula I exhibit antihypertensive activity, as indicated in standard tests, e.g. in the Grollman rat test [see A. Grollman, Proc. Soc. Expt. Biol. and Med. 57, 104 (1944)J on s.c. administration of from 0.1 to 10 mg/kg animal body weight of the compounds.
  • an indicated daily dose is from about 5 to about 1000 mg, conveniently given in divided doses 2 to 4 times a day in unit dosage form containing about 1.25 mg to about 500 mg, or in sustained release form.
  • the compounds of formula I may be administered in the form of a pharmaceutical composition.
  • the present invention accordingly provides a pharmaceutical composition comprising a compound of formula I in association with a pharmaceutical carrier or diluent.
  • Such compositions may be prepared by conventional techniques to be in conventional forms, for example capsules or tablets.
  • the compounds of Examples 1 and 2 are the preferred compounds.
  • the coronary insufficiency utility is preferred utility.
  • R is hydrogen, alkyl, alkenyl, cycloalkyl of 3 to 6 carbon atoms or phenylalkyl; the phenyl ring being unsubstituted or substituted by one, two or three substituents chosen from one or two halogen radicals, one or two alkyl groups of 1 to 4 carbon atoms, one to three alkoxy groups of 1 to 4 carbon atoms; R 3 and R 4 , indpendently, are alkyl, alkenyl, cycloalkyl of 3 to 6 carbon atoms, alkoxy, hydroxyalkoxy of 2 to 6 carbon atoms, alkoxyalkoxy of 3 to 6 carbon atoms, hydroxyalkoxyalkoxy of 4 to 8 carbon atoms, alkenyloxy, or cycloalkyloxy of 3 to 6 carbon atoms, and R 6 is other than alkylsulfonyl.
  • R is hydrogen
  • R 2 and R 5 are each alkyl, especially methyl
  • R 3 and R 4 are each alkoxy, especially ethoxy
  • R e is hydrogen or halogen, especially chlorine, especially in the 4 position
  • the dihydropyridine moiety is in the 4 or 5 position
  • X is S.
  • R is hydrogen
  • R 2 and R 5 are each alkyl, especially methyl
  • R 3 and R 4 are each alkyl or alkoxy, especially methyl, ethyl, tert. butyl, methoxy, ethoxy or tert. butyloxy
  • R- is hydrogen or halogen, especially chlorine, or alkoxy, especially methoxy
  • the dihydropyridine moiety is in the 4 or 5 position and R- is in the 4, 5 or 7 position.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Description

  • The present invention relates to dihydropyridine derivatives.
  • The present invention provides compounds of formula I,
    Figure imgb0001
    wherein
    • R, is hydrogen, alkyl or 1 to 6 carbon atoms, alkenyl or alkynyl or 3 to 6 carbon atoms, cycloalkyl of 3 to 7 carbon atoms, cycloalkylalkyl of 4 to 8 carbon atoms, phenylalkyl of 7 to 9 carbon atoms or phenylalkenyl of 9 to 12 carbon atoms, the phenyl ring being unsubstituted or mono, di- or trisubstituted independently by haloen, hydroxy or alkyl or alkoxy of 1 to 4 carbon atoms,
    • R2 and R6, independently, are hydrogen or alkyl of 1 to 6 carbon atoms,
    • R3 and R4 independently, are alkyl of 1 to 6 carbon atoms, alkenyl or alkynyl of 3 to 6 carbon atoms, cycloalkyl of 3 to 7 carbon atoms, cycloalkylalkyl of 4 to 8 carbon atoms, alkoxy of 1 to 6 carbon atoms, hydroxyalkoxy of 2 to 6 carbon atoms, alkoxyalkoxy of 3 to 6 carbon atoms, hydroxyalkoxyalkoxy of 4 to 8 carbon atoms, alkenyloxy or alkynyloxy of 3 to 6 carbon atoms, cycloalkyloxy of 3 to 7 carbon atoms or cycloalkylalkoxy of 4 to 8 carbon atoms,
    • RS is hydrogen, halogen, alkyl or alkoxy or alkylthio or alkylsulfonyl, each of 1 to 4 carbon atoms, trifluoromethyl, nitro or hydroxy, and
      X is oxygen or sulphur.
  • In any of the above radicals alkyl of 1 to 6 carbon atoms is preferably of 1 to 4 carbon atoms, especially of 1 to 2 carbon atoms. Any alkyl, alkoxy, alkylthio or or alkylsulfonyl radical of 1 to 4 carbon atoms is preferably of 1 or 2 carbon atoms. The alkyl moiety of cycloalkylalkyl or cycloalkyalkoxy is conveniently methyl. Halogen means fluorine, chlorine or bromine and is especially chlorine. Cycloalkyl or the cycloalkyl moiety of cycloalkylalkyl or cycloalkylalkoxy is conveniently cyclopropyl or cyclopentyl or cyclohexyl. The multiple bond of alkenyl, alkynyl, alkenyloxy, alkynyloxy or phenylalkenyl is preferably not in the α, β position. Alkenyl, alkenyloxy, alkynyl or alkynyloxy preferably has 3 to 5 carbon atoms. Alkenyl or the alkenyl moiety of alkenyloxy is conveniently allyl or 2-methylallyl. Alkynyl or the alkynyl moiety of alkynyloxy is conveniently propynyl. Phenylalkenyl preferably has the trans-configuration and is for example cinnamyl. When R, is optionally substituted phenylalkyl, the phenyl group is preferably unsubstituted. When the phenyl group is di- or tri-substituted, preferably the substituents are the same. When R3 and/or R4 is alkoxy, this is preferably ethoxy or methoxy. When R3 and/or R4 is alkoxyalkoxy or hydroxyalkoxyalkoxy, preferably the carbon chain between the two ether oxygen atoms is of 2 carbon atoms. The hydroxy group of hydroxyalkoxy or of hydroxyalkoxyalkoxy is preferably not attached to the carbon atom attached to an ether oxygen atom. R, is preferably hydrogen. R2 is conveniently identical to R5. R2 and/or R5 is preferably methyl. R3 and/or R4 is preferably alkoxy or alkoxyalkoxy, especially n-butyloxyethoxy. R. is conveniently halogen, alkyl or alkoxy, or especially hydrogen. R6 is conveniently adjacent to the dihydropyridine moiety which in turn is conveniently in the 4-position.
  • The present invention also provides a process for the production of a compound of formula I as defined above, comprising replacing the moiety -HC=Y in a compound of formula II,
    Figure imgb0002
    wherein R6 and X are as defined above, and -HC=Y is
    • i) formyl,
    • ii) a radical of formula
      Figure imgb0003
      or
    • iii) a radical of formula
      Figure imgb0004
      wherein z and z' are independently oxygen or NR,, and
    • R, to R5 are as defined above, by a moiety of formula III,
      Figure imgb0005
      wherein R, to R5 are as defined above.
  • The process may be effected in conventional manner for analogous dihydropyridine syntheses, e.g. according to Hantzsch. When the moiety -HC=Y is formyl and when it is desired to produce a compound of formula I, wherein R2 is identical to R5 and R3 is identical to R4, it is convenient to react a compound of formula II with a compound of formula IV,
    Figure imgb0006
    wherein R4 and R5 are as defined above, in the presence of a compound of formula V,
    Figure imgb0007
    wherein R, is as defined above.
  • Preferably at least 2 moles of a compound of formula IV per mole of a compound of formula II are present. Alternatively a compound of formula II may be reacted with a compound of formula VI,
    Figure imgb0008
    wherein R1, R4 and R5 are as defined above.
  • Preferably at least 2 moles of a compound of formula VI per mole of a compound of formula II are present. Preferably also R, is hydrogen.
  • When the moiety -HC=Y is formyl and preferably when it is desired to produce a compound of formula I wherein R2 is different to R5 and/or R3 is different to R4. it is also possible to react such a compound of formula II with a compound of formula IV and a compound of formula VII,
    Figure imgb0009
    wherein R2, R, and R3 are as defined above.
  • It will be appreciated that a compound of formula VI may be formed as an intermediate during the reaction of a compound of formula IV and a compound of formula V. A compound of formula II, wherein -HC=Y is a radical ii) or iii), may be formed as an intermediate in the above reactions. They may however be produced by different processes.
  • Alternatively or particularly for the production of a compound of formula I, wherein R2 is different to R5 and/or R3 is different to R4, it is convenient to react a compound of formula II, wherein the moiety -HC=Y is a radical ii) with a compound of formula IV or VI, and where appropriate, with a compound of formula V. A compound of formula II, wherein the moiety -HC=Y is a radical iii) may be an intermediate.
  • In the above reactions it is possible in certain instances when R2, R3, R4 and R5 are not identical that more than one isomer of formula I may be formed. If so these may be separated in conventional manner, e.g. by thin layer chromatography.
  • When the starting material is a compound of formula II, wherein -HC=Y is a radical iii), the reaction is a ring cyclisation. When Z and Z' are both oxygen, then an amine of formula V should be present.
  • However, all the above reactions may be effected under the same conditions.
  • The reaction may be effected conveniently in solution. A suitable solvent is water, ethanol, dioxane, dimethyl formamide, dimethyl sulphoxide, pyridine or glacial acetic acid. Suitable reaction temperatures may be from 20 to 160°C, preferably from 60 to 120°C.
  • Insofar as the production of starting materials is not particularly described these compounds are known or may be produced in analogous manner to known compounds.
  • In the following Examples the temperatures given are in degrees Centigrade and are uncorrected.
    • Example 1 4-(2,1,3-Benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid diethyl ester
  • 3.2 g of 2,1,3-benzoxadiazole-4-aldehyde, 5.7 g of acetoacetic acid ethyl ester, 2.5 ml of concentrated ammonia and 10 ml of ethanol are refluxed for 6 hours. The mixture is subsequently evaporated and the residual oil is chromatographed on silica gel with chloroform/acetic acid ester (9:1) to yield the title compound. The product is recrystallised from toluene, m.p. 153-155°.
  • By using the process described in Example 1, and corresponding starting compounds, e.g. a compound of formula II, wherein -HC=Y is a radical i) and compounds of formula IV and V, and for Examples 18 and 19 a compound of formula 11, wherein -HC=Y is a radical ii), wherein Z is oxygen and a compound of formula VI, the following compounds of formula I may be obtained, wherein y indicates the position of the dihydropyridine moiety:
    Figure imgb0010
  • The compounds of formula I exhibit pharmacological activity. In particular, they lead to a dilation of the coronary vessels as demonstrated by the results of tests measuring the blood flow to the myocardium of an anaesthetised cat by means of the microsphere method upon the administration of the active substance i.v. or i.d. The compounds of formula I also possess a favourable effect against angina pectoris, as shown by the increase of the coronary flow of an anaesthetised cat upon administration of the active substance.
  • The compounds of formula 1 are therefore indicated for use in the treatment of coronary insufficiency. For this use an indicated daily dose is from about 5 to 100 mg, conveniently administered in divided doses 2 to 4 times a day in unit dosage form containing from about 1.25 to about 50 mg, or in sustained release form.
  • Additionally, the compounds of formula I exhibit antihypertensive activity, as indicated in standard tests, e.g. in the Grollman rat test [see A. Grollman, Proc. Soc. Expt. Biol. and Med. 57, 104 (1944)J on s.c. administration of from 0.1 to 10 mg/kg animal body weight of the compounds.
  • The compounds are therefore further indicated for use as anti-hypertensive agents. For this use an indicated daily dose is from about 5 to about 1000 mg, conveniently given in divided doses 2 to 4 times a day in unit dosage form containing about 1.25 mg to about 500 mg, or in sustained release form.
  • The compounds of formula I may be administered in the form of a pharmaceutical composition. The present invention accordingly provides a pharmaceutical composition comprising a compound of formula I in association with a pharmaceutical carrier or diluent. Such compositions may be prepared by conventional techniques to be in conventional forms, for example capsules or tablets.
  • The compounds of Examples 1 and 2 are the preferred compounds. The coronary insufficiency utility is preferred utility.
  • In a group of compounds R, is hydrogen, alkyl, alkenyl, cycloalkyl of 3 to 6 carbon atoms or phenylalkyl; the phenyl ring being unsubstituted or substituted by one, two or three substituents chosen from one or two halogen radicals, one or two alkyl groups of 1 to 4 carbon atoms, one to three alkoxy groups of 1 to 4 carbon atoms; R3 and R4, indpendently, are alkyl, alkenyl, cycloalkyl of 3 to 6 carbon atoms, alkoxy, hydroxyalkoxy of 2 to 6 carbon atoms, alkoxyalkoxy of 3 to 6 carbon atoms, hydroxyalkoxyalkoxy of 4 to 8 carbon atoms, alkenyloxy, or cycloalkyloxy of 3 to 6 carbon atoms, and R6 is other than alkylsulfonyl.
  • Conveniently R, is hydrogen, R2 and R5 are each alkyl, especially methyl, R3 and R4 are each alkoxy, especially ethoxy, Re is hydrogen or halogen, especially chlorine, especially in the 4 position, the dihydropyridine moiety is in the 4 or 5 position, and X is S.
  • Alternatively conveniently R, is hydrogen, R2 and R5 are each alkyl, especially methyl, R3 and R4 are each alkyl or alkoxy, especially methyl, ethyl, tert. butyl, methoxy, ethoxy or tert. butyloxy, R- is hydrogen or halogen, especially chlorine, or alkoxy, especially methoxy, the dihydropyridine moiety is in the 4 or 5 position and R- is in the 4, 5 or 7 position.

Claims (11)

1. A process for the production of a compound of formula I,
Figure imgb0011
wherein
R, is hydrogen, alkyf of 1 to 6 carbon atoms, alkenyl or alkynyl of 3 to 6 carbon atoms, cycloalkyl of 3 to 7 carbon atoms, cycloalkylalkyl of 4 to 8 carbon atoms, phenylalkyl of 7 to 9 carbon atoms or phenylalkenyl of 9 to 12 carbon atoms, the phenyl ring being unsubstituted or mono, di- or trisubstituted independently by halogen, hydroxy or alkyl or alkoxy or 1 to 4 carbon atoms,
R2 and R5, independently, are hydrogen or alkyl of 1 to 6 carbon atoms,
R3 and R4 independently, are alkyl of 1 to 6 carbon atoms, alkenyl or alkynyl of 3 to 6 carbon atoms, cycloalkyl of 3 to 7 carbon atoms, cycloalkylalkyl of 4 to 8 carbon atoms, alkoxy of 1 to 6 carbon atoms, hydroxyalkoxy of 2 to 6 carbon atoms, alkoxyalkoxy of 3 to 6 carbon atoms, hydroxyalkoxyalkoxy of 4 to 8 carbon atoms, alkenyloxy or alkynyloxy of 3 to 6 carbon atoms, cycloalkyloxy of 3 to 7 carbon atoms or cycloalkylalkoxy of 4 to 8 carbon atoms,
R8 is hydrogen, halogen, alkyl or alkoxy or alkylthio or alkylsulfonyl, each of 1 to 4 carbon atoms, trifluoromethyl, nitro or hydroxy, and
X is oxygen or sulphur, which comprises chemically converting the moiety -HC=Y in a compound of formula II,
Figure imgb0012
wherein Rs and X are as defined above, and -HC=Y is
i) formyl,
ii) a radical of formula
Figure imgb0013
or
iii) a radical of formula
Figure imgb0014
wherein z and z' are independently oxygen or NR1, and
R, to R5 are as defined above, into a moiety of formula III,
Figure imgb0015
wherein R, to Rs are as defined above.
2. A compound of formula 1, as defined in claim 1.
3. A compound of claim 2, wherein R, is hydrogen.
4. A compound of claim 2, wherein R2 and R5 are methyl.
5. A compound of claim 2, wherein at least one of R3 and R4 is alkoxy or alkoxyalkoxy.
6. A compound of claim 2, wherein R6 is hydrogen.
7. A compound of claim 2, wherein R, is hydrogen, alkyl, alkenyl, cycloalkyl of 3 to 6 carbon atoms or phenylalkyl, the phenyl ring being unsubstituted or substituted by one, two or three substituents chosen from one or two halogen radicals, one or two alkyl groups of 1 to 4 carbon atoms, and one to three alkoxy groups of 1 to 4 carbon atoms, R3 and R4, independently, are alkyl, alkenyl, cycloalkyl of 3 to 6 carbon atoms, alkoxy, hydroxyalkoxy of 2 to 6 carbon atoms, alkoxyalkoxy of 3 to 6 carbon atoms, hydroxyalkoxyalkoxy of 4 to 8 carbon atoms, alkenyloxy or cycloalkoxy of 3 to 6 carbon atoms, and R6 is other than alkylsulphonyl.
8. A compound of claim 7, wherein R, is hydrogen, R2 and R5 are each alkyl, R3 and R4 are each alkyl or alkoxy, R6 is hydrogen or halogen or alkoxy, the dihydropyridine moiety is in the 4 or 5 position and R6 is in the 4, 5 or 7 position.
9. 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid diethyl ester.
10. A pharmaceutical composition comprising a compound of anyone of claims 2 to 9 in association with a pharmaceutical carrier or diluent.
11. A compound of formula I as defined in anyone of claims 2 to 9 for use as a pharmaceutical.
EP78100165A 1977-06-20 1978-06-15 Dihydropyridine derivatives, process for their production and pharmaceutical compositions containing them. Expired EP0000150B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CH752077 1977-06-20
CH7520/77 1977-06-20
CH286578 1978-03-16
CH2865/78 1978-03-16

Publications (2)

Publication Number Publication Date
EP0000150A1 EP0000150A1 (en) 1979-01-10
EP0000150B1 true EP0000150B1 (en) 1981-05-20

Family

ID=25691589

Family Applications (1)

Application Number Title Priority Date Filing Date
EP78100165A Expired EP0000150B1 (en) 1977-06-20 1978-06-15 Dihydropyridine derivatives, process for their production and pharmaceutical compositions containing them.

Country Status (20)

Country Link
EP (1) EP0000150B1 (en)
JP (1) JPS54103876A (en)
AT (1) AT376220B (en)
AU (1) AU524000B2 (en)
CA (1) CA1105463A (en)
CY (1) CY1239A (en)
DE (1) DE2860708D1 (en)
DK (1) DK149855C (en)
ES (1) ES470917A1 (en)
FI (1) FI64938C (en)
HK (1) HK65184A (en)
IE (1) IE47212B1 (en)
IL (1) IL54948A (en)
IT (1) IT1105364B (en)
LU (1) LU88342I2 (en)
MY (1) MY8500041A (en)
NL (1) NL930126I2 (en)
NZ (1) NZ187617A (en)
PT (1) PT68191A (en)
SG (1) SG20584G (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2316469A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH639659A5 (en) * 1978-12-18 1983-11-30 Sandoz Ag NEW 1,4-DIHYDROPYRIDINE DERIVATIVES, THEIR PRODUCTION AND USE.
FI793848A (en) * 1978-12-18 1980-06-19 Sandoz Ag BENZOXADIAZOLER OCH BENZOTHIADIAZOLER DERAS FRAMSTAELLNING OCH PHARMACEUTICAL COMPOSITION INNEHAOLLANDE DESSA
BE886259A (en) * 1979-11-23 1981-05-20 Sandoz Sa NOVEL DRUGS BASED ON 1,4-DIHYDROPYRIDINE DERIVATIVES FOR THE TREATMENT OF CEREBROVASCULAR DEFICIENCY OR WITH SPAMOLYTIC ACTION
CH655658B (en) * 1980-09-18 1986-05-15
FI813460L (en) * 1980-11-10 1982-05-11 Sandoz Ag NYA 4- (2,1,3-BENZOXADIAZOL-4-YL) -1,4-DIHYDRO-PYRIDIN DERIVATIVES DERAS FRAMSTAELLNINGSFOERFARANDE OCH DESSA INNEHAOLLANDE PHARMACEUTICAL COMPOSITION
DE3269219D1 (en) * 1981-11-17 1986-03-27 Fisons Plc Dihydropyridines, methods for their production and their formulation and use as pharmaceuticals
DE3207982A1 (en) * 1982-03-05 1983-09-08 Bayer Ag, 5090 Leverkusen NEW 1,4-DIHYDROPYRIDINE, METHOD FOR THE PRODUCTION AND USE THEREOF IN MEDICINAL PRODUCTS
DE3208628A1 (en) * 1982-03-10 1983-09-22 Bayer Ag, 5090 Leverkusen NEW COMPOUNDS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICINAL PRODUCTS
ZA83959B (en) * 1982-03-10 1984-09-26 Sandoz Ltd 1,4-dihydropyridine derivatives,their preparation and pharmaceutical compositions containing them
FR2528431B1 (en) * 1982-06-15 1986-01-10 Sandoz Sa NOVEL 1,4-DIHYDROPYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
FR2554109A1 (en) * 1983-11-01 1985-05-03 Sandoz Sa NOVEL 1,4-DIHYDROPYRIDINE DERIVATIVES, THEIR PREPARATION AND USE IN THERAPEUTICS AS MEDICAMENTS
IE57810B1 (en) * 1984-03-27 1993-04-21 Delagrange Lab 1,4-dihydropyridine derivatives,their preparation and their use
HU198844B (en) * 1984-06-14 1989-12-28 Sandoz Ag Process for producing new galenic pharmaceutical composition ensuring retarded release of active ingredient
GB8428552D0 (en) * 1984-11-12 1984-12-19 Sandoz Ltd Organic compounds
US5260321A (en) * 1984-11-12 1993-11-09 Sandoz Ltd. Use of 1,4-dihydropyridine derivatives and combinations thereof with calcitonins
GB8616047D0 (en) * 1986-07-01 1986-08-06 Sandoz Ltd A 1 4-dihydropyridine derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1552911A (en) * 1975-07-02 1979-09-19 Fujisawa Pharmaceutical Co 1,4 dihydropyridine derivatives and the preparation thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2316469A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine

Also Published As

Publication number Publication date
HK65184A (en) 1984-08-31
IL54948A (en) 1982-01-31
IT7849939A0 (en) 1978-06-19
DK262578A (en) 1978-12-21
NL930126I1 (en) 1993-11-01
ATA443178A (en) 1984-03-15
JPS54103876A (en) 1979-08-15
AU3725278A (en) 1980-01-03
IE781231L (en) 1978-12-20
NL930126I2 (en) 1995-02-16
FI781867A (en) 1978-12-21
ES470917A1 (en) 1979-10-01
DK149855C (en) 1987-04-21
FI64938C (en) 1984-02-10
EP0000150A1 (en) 1979-01-10
AT376220B (en) 1984-10-25
MY8500041A (en) 1985-12-31
DK149855B (en) 1986-10-13
IE47212B1 (en) 1984-01-25
SG20584G (en) 1985-03-08
IL54948A0 (en) 1978-08-31
CA1105463A (en) 1981-07-21
NZ187617A (en) 1980-12-19
LU88342I2 (en) 1994-05-04
IT1105364B (en) 1985-10-28
CY1239A (en) 1984-06-29
DE2860708D1 (en) 1981-08-27
FI64938B (en) 1983-10-31
PT68191A (en) 1978-07-01
JPS6360755B2 (en) 1988-11-25
AU524000B2 (en) 1982-08-26

Similar Documents

Publication Publication Date Title
EP0000150B1 (en) Dihydropyridine derivatives, process for their production and pharmaceutical compositions containing them.
EP0094159B1 (en) Dihydropyridine derivatives, their production and use
US3985758A (en) 1,4-Dihydropyridine derivatives
RU2245881C2 (en) Dihydropyrimidines, intermediate products and medicinal agent
US4466972A (en) Benzoxadiazoles and benzothiadiazoles, their preparation and pharmaceutical compositions containing them
EP0170213B1 (en) Glutarimide antianxiety and antihypertensive agents
NL193066C (en) Methyl, isopropyl-4- (2,1,3-benzoxadiazol-4-yl) -2,6-dimethyl-1,4-dihydro pyridine-3,5-dicarboxylate and pharmaceutical composition containing this compound.
EP0040860B1 (en) Dibenzoxazepine derivative, process for preparing the same and pharmaceutical composition comprising the same
IE51267B1 (en) 1,4-dihydropyridine compounds having different substituents in the 2-position and 6-position,their production,and their medicinal use
US4642310A (en) Circulation-active tetrahydrothienopyridines
EP0115142B1 (en) Chroman compounds
CA1208639A (en) 1,4-dihydropropyridine derivatives, in optically active or in racemate form and their production and pharmaceutical compositions
US4612312A (en) Glutarimide antianxiety and antihypertensive agents
US4874773A (en) 3-Aminocarbonyl-1,4-dihydropyridine-5-carboxylic acid compounds, and pharmaceutical composition containing the same
JPS6024794B2 (en) Oxadiazolopyrimidine derivatives
US4336192A (en) 5,6-Dihydro-11-alkylene-morphanthridin-6-ones
US4029795A (en) 4(2' Isoquinolin-1-one)piperidines
US4647568A (en) Circulation-active hydroxy-tetra-hydropyridinelactones
EP0264232A1 (en) 2-Azetidinone derivatives
US4278798A (en) 1-Ethyl-1,4-dihydro-6-(2-naphthyl)-4-oxonicotinic acid and esters thereof
US3557100A (en) Certain decahydro and dodecahydro-5h-pyrido(1,2-a) - 1,6 - naphthyridine - 5 - ones,the corresponding - 5 - ols and derivatives thereof
GB2051054A (en) Pyrazolo (1,5-c) quinazoline derivatives and a process for the preparation thereof
JPH0220638B2 (en)
US4675329A (en) Isopropyl 2-(3-trifluoromethylphenoxy)-ethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-pyridine-3,5-dicarboxylate as vaso-dilators
US4314063A (en) 1-Ethyl-1,4,5,6-tetrahydro-6-(2-naphthyl)-4-oxo-nicotinic acid and lower alkyl esters thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE FR GB LU NL SE

17P Request for examination filed
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): BE CH DE FR GB LU NL SE

Designated state(s): BE CH DE FR GB LU NL SE

REF Corresponds to:

Ref document number: 2860708

Country of ref document: DE

Date of ref document: 19810827

REG Reference to a national code

Ref country code: FR

Ref legal event code: CC

Free format text: FRCC 92C0176, 920507

REG Reference to a national code

Ref country code: FR

Ref legal event code: CB

Free format text: FRCB 92C0176, 780615

REG Reference to a national code

Ref country code: FR

Ref legal event code: CL

EPTA Lu: last paid annual fee
EAL Se: european patent in force in sweden

Ref document number: 78100165.6

REG Reference to a national code

Ref country code: NL

Ref legal event code: KC1

Free format text: NLKC1 930126, 980615, EXPIRES:20030614

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19970421

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19970423

Year of fee payment: 20

Ref country code: DE

Payment date: 19970423

Year of fee payment: 20

Ref country code: BE

Payment date: 19970423

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19970424

Year of fee payment: 20

Ref country code: GB

Payment date: 19970424

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19970428

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19970515

Year of fee payment: 20

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Free format text: SANDOZ AG TRANSFER- NOVARTIS AG

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19970616

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

NLS Nl: assignments of ep-patents

Owner name: NOVARTIS AG

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

BE20 Be: patent expired

Free format text: 980615 *SANDOZ A.G.

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 19980614

Ref country code: CH

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 19980614

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 19980615

Ref country code: LU

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 19980615

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Effective date: 19980614

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

NLV7 Nl: ceased due to reaching the maximum lifetime of a patent

Effective date: 19980615

EUG Se: european patent has lapsed

Ref document number: 78100165.6

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT